Data
- - - Truveta Data
      
      A complete, living view of patient care
    - Explore Truveta Data
  - - Capabilities
      
      Representative, complete, and real-time
  - - Therapeutic areas
      
      Explore every disease with longitudinal, clinical context
    - All therapeutic areas
    - Featured therapeutic areas
  - - Evidence
      
      Build trust through rigorous analytics and expertise
    - - Trusted research environment
      - Evidence Services
Intelligence
- - - Truveta Intelligence
      
      Answers in minutes, not months
    - Explore Truveta Intelligence
  - - Capabilities
      
      Ask what matters now
    - - Ask
  - - Evidence
      
      Verify the methodology behind the results
    - - Verify
Customers
- - - Truveta customers
      
      Trusted by leading life science, public health, and healthcare organizations
  - - Who we serve
Research
About
- - - Saving Lives with Data
      
      Built with and owned by US health systems to improve patient care
Contact us
Sign in



Close

Research

Featured research

Rising rate of non-receipt of vitamin K for newborns, January 2019–June 2026

Rising rate of non-receipt of vitamin K for newborns, 2019–June 2026

Truveta Research finds documented newborn vitamin K non-receipt rose from 5.2% in January to 8.1% in June 2026, continuing a recent upward trend.

Graphic from Truveta showing a record increase in GLP-1 prescribing among older adults following the launch of Medicare's GLP-1 Bridge program, with trend lines illustrating prescribing growth over time.

Older adults see record increase in GLP-1 prescribing following Medicare GLP-1 Bridge program

July 2026 marked the largest month-to-month increase in GLP-1 prescribing among adults aged 65 years and older observed during the study period. AOM tirzepatide and AOM semaglutide showed the largest gains following launch of the Medicare GLP-1 Bridge, increasing...

Truveta research graphic titled '2026 Cyclosporiasis Outbreak: Diagnoses Reach Historic Levels,' featuring outbreak trend lines that illustrate a significant rise in cyclospora diagnoses during summer 2026

Cyclosporiasis diagnoses reach historic levels in 2026 summer outbreak

During July 2026, the rate of cyclosporiasis diagnosis reached 10.5 per 100,000 people with a healthcare encounter, more than 11-fold higher than the average July rate observed between 2018 and 2025 (0.9 per 100,000). More than 1 in 5 patients with a cyclosporiasis...

early uptake of GLP-1 Foundayo pill for obesity

Early uptake of oral orforglipron (Foundayo pill) for obesity following FDA approval

More than 2 in 5 patients (40.3%) initiating oral orforglipron (Foundayo pill) had no prior evidence of GLP-1-based medication use, suggesting early uptake extends beyond patients already receiving injectable therapies. Among patients with prior GLP-1-based medication...

Truveta graphic promoting research on e-bike and e-scooter injuries, featuring the headline "E-bike and e-scooter injuries rising rapidly" with a subtitle highlighting increasing emergency department visits among children and adolescents over a background line chart of injury trends.

Emergency department visits related to e-bike and e-scooter injuries are rising rapidly among children and adolescents

Truveta Research finds e-bike and e-scooter injury ED visits rose 7.5-fold among children, with head and neck injuries most common.

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular